Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Agile Therapeutics to Present at Upcoming Investor Conferences

AGRX

PRINCETON, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29th Annual Healthcare Conference on Tuesday March 19, 2019 at 10:55 AM Eastern Time.  The conference will be held at the Westin New York Grand Central Hotel, New York, NY.

Additionally, on March 18, 2019, Al Altomari, the Company’s Chairman and CEO, will participate in a panel at the 31st Annual ROTH Conference in Dana Point, CA and present the Company’s overview presentation, which is currently available on the Investor Relations section of the Agile Therapeutics website.

To access the live and archived webcast of the Company’s presentation at Oppenheimer’s 29th Annual Healthcare Conference, visit the Investor Relations section of the Agile Therapeutics website at www.agiletherapeutics.com.  The webcast will be archived on the Agile Therapeutics website for 60 days following the event.

About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website. 

Contact:  Investor Relations -- 609-683-1880

Primary Logo